AstraZeneca Group (AZN)
Your Dashboard
Displaying AZN Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 8.945B
- Accounts Receivable 8.511B
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.6268
- Beneish M-Score Pro
- Beta Pro
- Book Value 21.72B
- Book Value per Share 16.81
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing -3.438B
- Cash Financing TTM -8.952B
- Cash Investing 593.00M
- Cash Investing TTM -1.529B
- Cash Operations 1.54B
- Cash Operations TTM 7.471B
- Cash and Equivalents 6.143B
- Cash and ST Investments 6.332B
- Current Ratio 1.365
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.432
- Dividend
- Dividend Yield 9.50%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share 1.28
- Earnings Per Share Growth -38.16%
- Earnings Per Share TTM 6.52
- Earnings Yield 15.81%
- Effective Tax Rate TTM Pro
- Enterprise Value 56.52B
- Expenses 5.709B
- Expenses TTM 23.92B
- Free Cash Flow 1.543B
- Free Cash Flow TTM 6.874B
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 81.29%
- Gross Profit TTM 26.59B
- Income from Cont. Ops Pro
- Interest Expense 0.00
- Interest Income
- Inventories 2.04B
- KZ Index Pro
- Liabilities 29.04B
- Long Term Debt 9.383B
- Market Cap 53.28B
- Net Income 1.64B
- Net Income TTM 8.723B
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio 6.324
- PE Value Pro
- PEG Ratio 0.4587
- PS Value Pro
- Payout Ratio TTM Pro
- Price 41.23
- Price / Book Value 2.453
- Price / Sales Ratio 1.632
- Price / Tangible Book Value Pro
- Profit Margin 22.32%
- R&D Expense 1.53B
- Receivables Turnover 3.851
- Retained Earnings 16.03B
- Retained Earnings Growth -16.71%
- Return on Assets 16.51%
- Return on Equity 37.69%
- Return on Invested Capital Pro
- Revenue Growth -11.37%
- Revenue Per Share TTM 25.26
- Revenues 7.349B
- Revenues TTM 32.65B
- SG&A Expense 2.537B
- Shareholders Equity 21.72B
- Shares Outstanding 1.292B
- Stock Buybacks 912.00M
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 50.76B
- Total Return Price 41.23
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these AZN related companies
AZN News
$AZN stop at 40 on 1/3. Have owned a ton of it since early '10. Cost basis ~46 (not inc. divies)
about 4 days ago by WallStreetBean
about 4 days ago by WallStreetBean
RT @SeemaCnbc Cancer data expected to move big pharma $JNJ $PFE $AZN
about 10 days ago by StockTwits
about 10 days ago by StockTwits
$AZN “no longer operating in isolation as a pharmaceutical organization.” http://stks.co/3nwQ
about 14 days ago by WallStreetBean
about 14 days ago by WallStreetBean
AstraZeneca (AZN) Says SYMBICORT Shows Similar Safety Profile to Budesonide in Certain Asthma Patient Groups
May 10, 9:02AM Street Insider
May 10, 9:02AM Street Insider
UPDATE - Canaccord Genuity Downgraded Ardea Biosciences (RDEA) To 'Hold'; Q1 Is Non-Event In Light Of Acquisition By AZN
May 08, 9:14AM Street Insider
May 08, 9:14AM Street Insider
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 20 days ago by abubnic
about 20 days ago by abubnic
$AMRN U.K.'s second-biggest drugmaker, pharmaceutical giant $AZN, based in London is sniffing around Ireland's small biotech $AMRN
about 23 days ago by JasonMilano8
about 23 days ago by JasonMilano8
News related to $AZN, currently +0.3% since open: 'Impax Labs falls on weak sales, new FDA warning' http://stks.co/3bhx
about 26 days ago by TradeBot
about 26 days ago by TradeBot
what kinda drug is that? RT @JNapodano $AZN reported $16M in sales of Vimovo - not great, but still higher than consensus. $POZN.
about 27 days ago by WallStreetBean
about 27 days ago by WallStreetBean
Morning News: April 26, 2012 | via @EddyElfenbein http://stks.co/3Wht $FED $DB $NDX $AAPL $CAT $AZN
about 31 days ago by STNet
about 31 days ago by STNet
$AZN trouble in paradise: AstraZeneca CEO to step down as Q1 profit plunges http://stks.co/3WZ3 (holding)
about 31 days ago by WallStreetBean
about 31 days ago by WallStreetBean
News related to $AZN: 'AstraZeneca CEO to step down as Q1 profit plunges' http://stks.co/3WIC
about 32 days ago by TradeBot
about 32 days ago by TradeBot
@taketheplunge $AMRN $AZN has been linked to every biotech on the market in the last 3 months. $AZN could buy...
about 32 days ago by jackofalltrade
about 32 days ago by jackofalltrade
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 41.23 | +0.05 | +0.12% | 53.28B |
| AZK | 4.72 | +0.11 | +2.39% | 769.97M |
| AZC | 1.63 | +0.13 | +8.67% | 235.05M |
| AYR | 11.60 | +0.37 | +3.29% | 839.61M |
| BCRX | 3.26 | +0.00 | +0.00% | 150.09M |
| BCR | 99.90 | -0.09 | -0.09% | 8.473B |
| BCPC | 30.31 | -0.25 | -0.82% | 885.36M |
| BCOM | 4.20 | +0.01 | +0.24% | 125.54M |
| BCO | 23.23 | -0.32 | -1.36% | 1.089B |
| BCH | 84.05 | +0.83 | +1.00% | 12.18B |
